Aripiprazole
Product Images NDC 53808-1101

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 53808-1101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 5mg (Aripiprazole 5mg)

Label for Aripiprazole 5 mg tablets from DOH Central Pharmacy. The package contains 30 tablets and is for prescription use only. The label includes the lot number, expiration date of 08-17-2018, and the pharmacy location in Tallahassee, FL. A barcode and UPC are also visible.*

FDA Label Image

C103b8f2-figure-01 (Aripiprazole Tablets 1)

Chemical structure diagram of the active ingredient Aripiprazole, showing the molecular arrangement with labeled chlorine atoms and various ring systems connected by chains.*

FDA Label Image

Fig-1 (Aripiprazole Tablets 2)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold changes and 90% confidence intervals for AUC and Cmax relative to a reference without interacting drugs. The chart presents the impact of various drugs including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam) on Aripiprazole pharmacokinetics.*

FDA Label Image

Fig-2 (Aripiprazole Tablets 3)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing the fold change and 90% confidence interval of Dehydro-Aripiprazole levels relative to reference without interacting drugs. It compares the impact of various CYP3A4 and CYP2D6 inhibitors, inducers, gastric acid blockers, and other drugs on parameters AUC and Cmax.*

FDA Label Image

Fig-3 (Aripiprazole Tablets 4)

A plot illustrating the effect of Aripiprazole on various other drugs, showing fold change and 90% confidence intervals in pharmacokinetic parameters such as AUC and Cmax. The x-axis represents change relative to reference (without interacting drug) ranging from 0.5 to 3.0, while different drugs including dex­tromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram are listed on the y-axis with corresponding pharmacokinetic measurements.*

FDA Label Image

Fig-4 (Aripiprazole Tablets 5)

A pharmacokinetic chart showing Aripiprazole fold change and 90% confidence intervals in special populations. Variables include CYP2D6 metabolizer status, gender, age groups, hepatic impairment severities, and severe renal impairment with AUC and Cmax plotted against change relative to reference values.*

FDA Label Image

Fig-5 (Aripiprazole Tablets 6)

A forest plot showing the fold change and 90% confidence intervals of Dehydro-Aripiprazole pharmacokinetics (AUC and Cmax) under various conditions: CYP2D6 poor vs. extensive metabolizer, gender female vs. male, age groups 18-64 vs. >65 years old, and degrees of hepatic and renal impairment compared to normal. The x-axis represents change relative to a reference value.*

FDA Label Image

Fig-6 (Aripiprazole Tablets 7)

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over days from randomization for Aripiprazole versus placebo. The y-axis represents the proportion with relapse, and the x-axis represents days from randomization up to 182 days. The chart includes numbers of subjects at risk for both Aripiprazole and placebo groups below the x-axis.*

FDA Label Image

01 (Aripiprazole Tablets 8)

A Kaplan-Meier curve displaying the proportion of subjects with relapse over days from randomization for Aripiprazole versus placebo groups. The graph includes a risk table showing the number of subjects at risk at several time points. Aripiprazole shows a lower proportion with relapse compared to placebo throughout the study period up to 182 days.*

FDA Label Image

0102 (Aripiprazole Tablets 9)

A Kaplan-Meier survival curve chart comparing the proportion of subjects with relapse over 364 days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. The chart includes the number of subjects at risk over time for each group. Aripiprazole is represented by a solid line, placebo by a dashed line.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.